key: cord-0762560-u42xz3nv
authors: Liu, Kaiwei; Wang, Xin; Song, Guang
title: Association of epicardial adipose tissue with the severity and adverse clinical outcomes of COVID-19: A meta-analysis
date: 2022-04-11
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.04.013
sha: e8e8165f39e5f520be7123e7106988d9a5ebac02
doc_id: 762560
cord_uid: u42xz3nv

Objectives Epicardial adipose tissue (EAT) has been proposed to be an independent predictor of visceral adiposity. EAT measures are associated with coronary artery disease, diabetes, and chronic obstructive pulmonary disease, which are risk factors for COVID-19 poor prognosis. Whether EAT measures are related to COVID-19 severity and prognosis is controversial. Methods We searched six databases for studies until January 7, 2022. The pooled effects are presented as the standard mean difference (SMD) or weighted mean difference with 95% confidence intervals (CIs). The primary endpoint was COVID-19 severity. Adverse clinical outcomes were also assessed. Results 13 studies with a total of 2482 COVID-19 patients were identified. All patients had positive reverse transcriptase-polymerase chain reaction results. All quantitative EAT measures were CT-based. Patients in the severe group had higher EAT measures compared to the non-severe group (SMD = 0.74, 95% CI: 0.29–1.18, P = 0.001). Patients with hospitalization requirement, requiring invasive mechanical ventilation, admitted to intensive care unit, or with combined adverse outcomes had higher EAT measures compared to their controls (all P < 0.001). Conclusions EAT measures were associated with the severity and adverse clinical outcomes of COVID-19. EAT measures might help in prognostic risk stratification of patients with COVID-19.

More and more Coronavirus cases have been confirmed since December 2019. As of December 21, 2021, there have been over 273 million confirmed cases and over 5.3 million deaths worldwide (World Health Organization, 2021) . Hospitals, especially intensive care units (ICU), are currently overcrowded in some countries. Determining how to assess the severity quickly and predict the outcomes of COVID-19 (such as the need for hospitalization) after patients visiting an outpatient or emergency department began a research goal for doctors, which could efficiently allocate medical resources and help doctors make treatment-related decisions.

Early studies have revealed that obesity with a higher body mass index (BMI) is a risk factor for developing the critical condition in COVID-19 (Chang et al., 2020 , Chu et al., 2020 . Although widely used to assess obesity, BMI was not always an accurate prediction of adverse clinical outcomes of COVID-19 (Caussy et al., 2020 . This suggested that the relationship between obesity and the severity and mortality of COVID-19 is more complex. The underlying pathophysiologic mechanisms remain unclear.

Epicardial adipose tissue (EAT), an ectopic heart adipose, modulates the metabolic environment of both the coronary arteries and myocardium. EAT has close relationships with coronary artery disease, metabolic syndrome, diabetes, obstructive sleep apnea, and human immunodeficiency virus. Iacobellis et al. pioneered the research on EAT (Iacobellis, 2015 , Iacobellis et al., 2005 . EAT has been proposed as an independent predictor of visceral adiposity and may have a close relationship with adverse clinical outcomes of COVID-19, first reported by Malavazos, Goldberger, and Iacobellis in 2020 (Malavazos et al., 2020) .

EAT can be measured by chest computed tomography (CT) scan and echocardiography. EAT thickness, volume, and density/attenuation can be easily and precisely measured by CT scan using commercial software. Image analysis took approximately 3 min per patient (Conte et al., 2021) . Several studies have evaluated the relationship between EAT measures and COVID-19 severity (Deng et al., 2020 . However, small sample sizes and potential confounders, such as differences in EAT measures, can affect the strength of previous evidence. Therefore, this meta-analysis of studies was conducted to provide a more comprehensive summary of currently available research to explore the association of EAT measures with the severity and clinical outcomes of COVID-19.

We followed a reporting guideline (Preferred Reporting Items for Systematic Reviews and Meta-Analyses, PRISMA) to perform this study. A review protocol (CRD42022302104) with search strategy was registered in the PROSPERO International prospective register of systematic reviews.

Two independent investigators (KL and XW) independently searched PubMed, MEDLINE, Web of Science, Embase, Cochrane library, and medRxiv.org from database inception to January 7, 2022, to identify the relevant studies. The following search keywords included "COVID-19" and "epicardial adipose tissue". At the same time, we read the references of articles, trying to find the potential literature which may meet the criteria.

Two researchers (KL and XW) independently screened the titles and abstracts for eligibility. Full papers were assessed to confirm disagreement in existence according to the exclusion criteria by the two researchers. Disagreements were discussed and resolved by involving a third reviewer (GS) for adjudication.

Original studies were eligible if the following criteria were met: (I) COVID-19 with different related clinical outcomes or different severity; (II) quantitative assessment of EAT measures (EAT thickness, volume, or attenuation) by CT or echocardiography as soon as possible after presenting to the hospital; (III) text in English available. Original studies were ineligible if the following criteria existed: (I) reviews, case reports, or case series; (II) did not report the data necessary for calculating the mean and standard deviation of EAT measures; (III) animal studies. If there were several publications from the same study, the study with the most cases and relevant information was included.

The extracted data included the first author of involved studies, year of publication, country, participant number, gender, age, BMI, EAT measures, and outcomes.

Numeric data were gathered directly from tables or, when presented in graphs only, were inferred by digitizing the figure with GetData Graph Digitizer 2.26 (Li et al., 2017 ). The quality assessment was performed by the Newcastle-Ottawa Scale (NOS) assessment tool.

The clinical outcomes involved in the meta-analysis were death/survival, the need for invasive mechanical ventilation, the need for hospitalization, the need for ICU admission, or combined adverse outcomes. Combined adverse outcomes were the need for ICU admission, invasive mechanical ventilation, vasopressor therapy, or death (Bihan et al., 2021 , Grodecki et al., 2021 , Phan et al., 2021 . In our meta-analysis, severe or critical COVID-19 patients were grouped into the severe group, and mild or moderate COVID-19 patients were grouped into the non-severe group. The severity criteria of the involved studies were shown in Supplementary   Table S1 .

The pooled effects are presented as the weighted mean difference (WMD) or standard mean difference (SMD) with 95% confidence intervals (CIs). Heterogeneity was assessed using the I 2 statistic. If there was no heterogeneity (P > 0.1 or I 2 < 50%), a fixed-effects model was used to estimate the pooled effect; otherwise, a random-effects model was utilized. When heterogeneity existed, we conducted subgroup analyses based on "EAT measures" or "type of clinical outcomes".

Sensitivity analyses were directed to assess the influence of the individual study on the overall estimate. We analyzed the symmetry of a funnel plot to evaluate possible small sample effects and used Begg's and Egger's tests to evaluate publication bias in the included studies. A p-value < 0.05 was considered statistically significant for asymmetry. Trim-and-fill analysis was performed to 'normalize' the asymmetric funnel plot. Statistical analyses were performed using Stata (version 16.0; StataCorp, College Station, TX, USA).

We had searched potentially relevant publications from six sources. After applying the inclusion and exclusion criteria, 13 studies were identified , Bihan et al., 2021 , Conte et al., 2021 , Deng et al., 2020 , Grodecki et al., 2021 , Guarisco et al., 2021 , Phan et al., 2021 , Sevilla et al., 2022 , Slipczuk et al., 2021 , Turker Duyuler et al., 2021 (Figure 1) .

The baseline characteristics of the included studies were shown in Table 1 . All studies were published in these three years. Studies were conducted in Europe (France, Italy, and Spain), North America (USA), and Asia (China, Iran, and Turkey).

2482 patients with COVID-19 were included, who all had positive reverse transcriptase-polymerase chain reaction results. All quantitative EAT measures in these thirteen studies were CT-based. Eight studies evaluated the EAT volume, eight with EAT attenuation, three with EAT thickness. Six studies evaluated the association between EAT measures and the severity of COVID-19. Ten studies evaluated the association between EAT measures and clinical outcomes of COVID-19. The NOS score ranged from 7 to 9, indicating no low-quality study was involved (Supplementary Table S2 ).

A total of 1128 patients (336 in the severe group and 792 in the non-severe group)

were involved in the quantitative data synthesis. Patients in the severe group had higher EAT measures compared to the non-severe group (SMD = 0.74, 95% CI: 0.29-1.18, P = 0.001).

To investigate the possible sources of this heterogeneity (I 2 = 92.6%, P < 0.001), we carried out the subgroup analysis (Figure 2) . However, heterogeneity was not decreased after stratified by the type of EAT measures. Subgroup analysis indicated that significant results were observed in the EAT volume and EAT thickness subgroups (SMD = 0.62, 95% CI: 0.14-1.11, P = 0.012; SMD = 1.22, 95% CI: 0.97-1.47, P < 0.001).

After being stratified by the type of clinical outcomes, patients with combined adverse outcomes had higher EAT volume (in milliliter) compared to those without combined adverse outcomes (WMD = 49.61, 95% CI: 31.45-67.78, P < 0.001,

Patients admitted to ICU had higher EAT attenuation compared with patients without ICU admission (WMD = 13.07, 95% CI: 8.07-18.06, P < 0.001, Figure 4 ). Patients requiring IMV had higher EAT attenuation compared with patients without IMV requirement (WMD = 13.07, 95% CI: 8.07-18.06, P < 0.001, Figure 4) .

The EAT thickness (in millimeters) was significantly increased in the patients admitted to ICU compared to the patients without ICU admission (WMD = 0.89, 95% CI: 0.66-1.12, P < 0.001, Figure 5) . Meanwhile, the EAT thickness was significantly increased in patients with hospitalization requirements compared to patients without (WMD = 13.07, 95% CI: 8.07-18.06, P < 0.001, Figure 5 ).

There was no difference of EAT measures between non-survivor and survivor group (EAT volume: WMD = 13.43, 95% CI: -14.51-41.36, P = 0.346; EAT attenuation: CI: -0.28-3.88, P = 0.091).

To evaluate the robustness of the results, sensitivity analyses were performed by sequentially removing each study. No apparent change occurred for most outcomes when an individual study was omitted.

No publication bias was observed in our evaluation of the funnel plots for EAT measures with the severity of COVID-19, and this finding was confirmed by Begg's (P = 0.466) and Egger's (P = 0.991) tests; No publication bias was observed in our evaluation of the funnel plots for EAT volume with the clinical outcomes of COVID-19, and this finding was confirmed by Begg's (P = 0.707) and Egger's (P = 0.985) tests; No publication bias was observed in our evaluation of the funnel plots for EAT attenuation with the clinical outcomes of COVID-19, and this finding was confirmed by Begg's (P = 0.764) and Egger's (P = 0.069) tests. However, an obvious publication bias was revealed in our evaluation of the funnel plots for EAT attenuation with the clinical outcomes of COVID-19, confirmed by Begg's (P = 0.348) and Egger's (P = 0.001) tests; Thus, the trim-and-fill method was used to adjust the publication bias. After trimming, the results were similar, indicating that the results were statistically reliable (WMD = 0.84, 95% CI: 0.66-1.02, Figure 6 ).

This is the first meta-analysis that comprehensively summarized the association of EAT measures with the severity of COVID-19. Meanwhile, EAT measures had a close relationship with adverse clinical outcomes of COVID-19, and thus became a risk stratification tool for COVID-19 patients. The results were confirmed by subgroup analysis, sensitivity analysis, and publication bias test.

A previous study has confirmed that obesity increased the infection severity in BMI is a simple index and commonly used to classify overweight and obesity in adults. Recent meta-analysis papers demonstrated that non-linear relationship was observed between BMI and adverse clinical outcomes in patients with COVID-19 (Du et al., 2021 , Pranata et al., 2021b . One of the studies revealed the odds ratios for overweight patients and obesity patients were 1.02 (95% CI:0.99-1.05) and 1.09 (95% CI:1.04-1.15) when using BMI of 20 kg/m 2 as the reference (Pranata et al., 2021b) . Overweight COVID-19 patients with increased BMI probably didn't have a higher risk of adverse outcomes than normal-weight controls, consistent with several recently published studies (Kananen et al., 2021 , Tamara and Tahapary, 2020 , van Son et al., 2021 . That conclusion also suggested that the relationship between body fat and the severity/adverse outcome of COVID-19 is more complex.

There are some anthropometric tools as BMI complements to determine obesity, including waist circumference, waist-to-hip ratio, waist-to-height ratio, or visceral adiposity parameters (Sommer et al., 2020) . Meanwhile, researchers found the Edmonton Obesity Staging System, a clinical classification tool, was associated with adverse COVID-19 outcomes. This system distinguished risks beyond BMI (Rodriguez-Flores et al., 2022) . The limitation of this system is complicated and may not be suitable for patients who need urgent care. Recently studies have shown that visceral adiposity seems to be a better risk stratification tool in COVID-19, and patients with central obesity might need special attention (Foldi et al., 2021 , Pranata et al., 2021a . However, no standard CT protocol for visceral adiposity measurement (quantified at the different levels) may cause high heterogeneity of studies.

Abdominal CT is also not a routine exam for COVID-19 patients.

EAT, as ectopic visceral fat around the heart, makes up for the lack of BMI that does not reflect the mass of the visceral fat (Hamdy et al., 2006) . EAT is a potential source of inflammatory mediators, including Tumor Necrosis Factor-alpha (TNF-alpha), interleukins 1 and 6 (IL-1, IL-6), leptin, and monocyte chemoattractant protein-1, and become a marker of systemic inflammation (Shimabukuro et al., 2013 , Song et al., 2020 . Inflammation plays a major role in the pathogenesis and prognosis of COVID-19 (Feng et al., 2020) . Therefore, many studies have begun to verify the hypothesis that there are close relationships between EAT and severity/adverse outcomes of COVID-19. EAT can be measured by chest CT scan and echocardiography. EAT measurement by echocardiography was first developed by Iacobellis et al. (Iacobellis et al., 2003) .

However, echocardiography can only measure the EAT thickness, and the imaging quality may reduce due to COVID-19 pneumonia. Chest CT scan is a useful exam for suspected or confirmed COVID-19 patients, both in diagnosis and aids in clinical decision making (Garg et al., 2021) . Our meta-analysis revealed that EAT measures had a close relationship with the severity and adverse clinical outcomes of COVID-19. Therefore, EAT measures by chest CT scan on admission could be a risk stratification tool for COVID-19 patients. Meanwhile, EAT measures were associated with multiple inflammatory biomarkers and PaO 2 /FiO 2 ratio, which were proven to be effective predictors of COVID-19 progression , Guarisco et al., 2021 . The integration of EAT volume measurements into the clinical risk scores system for patients with COVID-19 can potentially enhance adverse outcome prediction (Conte et al., 2021 , Grodecki et al., 2021 , Guarisco et al., 2021 , Turker Duyuler et al., 2021 .

The mechanism of EAT measures in COVID-19 patients is not clear. EAT may exert the direct/paracrine and indirect/systemic effect in COVID-19. Based on the results of existing research (Conte et al., 2021 , Grodecki et al., 2021 , we propose the following: (I) EAT was associated with coronary artery disease, diabetes, chronic obstructive pulmonary disease, and old male which were risk factors for COVID-19 poor prognosis (Parohan et al., 2020) ; (II) COVID-19 infection could trigger systemic inflammatory response (Coperchini et al., 2020) . EAT may transduce this inflammation to the heart (Kim and Han, 2020, Malavazos et al., 2020) .

Meanwhile, EAT may exert a direct effect on the neighboring lungs and enhance systemic inflammatory response to COVID-19 (Moore and June, 2020, Ryan and Caplice, 2020) . The EAT which near the pulmonary artery enables direct diffuse the inflammatory mediators into the pulmonary circulation, which may then exert vasocrine or paracrine effects on the lung tissue (Grodecki et al., 2021) ; (III) EAT accumulation caused growth hormone-insulin-like growth factor 1 axis impairment which usually in old male patients, may further influence the pathophysiology of COVID-19 (Lubrano et al., 2020) ; (IV) COVID-19 infection could trigger system inflammation, including EAT inflammation. Viruses infect cells through the angiotensin converting enzyme 2 (ACE2) receptor, which is highly expressed in EAT (Couselo-Seijas et al., 2021) . A recent animal study found ACE2 deficiency could worsen EAT inflammation in diet-induced obesity mice (Patel et al., 2016) ; (V) The release of proinflammatory cytokines from EAT into the general circulation may contribute to the systemic inflammatory state in COVID-19; systemic inflammation, in turn, promotes accumulation of EAT, creating a positive feedback loop (Grodecki et al., 2021) .

Recently, Iacobellis et al. reported that 33 COVID-19 patients had reduced EAT attenuation after receiving the dexamethasone therapy compared with any of the other therapies (Iacobellis et al., 2021) . Therefore, EAT could serve as a therapeutic target for anti-inflammatory treatment in COVID-19 patients. More studies about EAT attenuation were suggested for COVID-19 in future. For those patients with an increased EAT measure, doctors may advise them to be hospitalized and prompt closer clinical observation for the possibility of myocardial injury and/or cardiac dysfunction (Özer et al., 2021 (Özer et al., , Wei et al., 2020 . Both statins and colchicine were proven to decrease EAT (Konwerski et al., 2022) . Recent studies have found these two drugs may reduce the mortality risk of COVID-19 patients (Chiu et al., 2021 , Diaz-Arocutipa et al., 2021 . There are several ongoing clinical trials (such as NCT04472611, NCT04904536, NCT05038449) that evaluate the efficacy and safety of these two drugs for COVID-19 patients. Therefore, statins and colchicine may be beneficial for COVID-19 patients with an increased EAT measure.

First, most studies were single center. Single race and the small sample size can't be ignored. All these disadvantages could reduce the credibility of the conclusion of this study. Second, high heterogeneity was found in most analyses. Subgroup analysis was performed. No source of heterogeneity was revealed. Third, some underlying confounders may not be adjustable in the involved studies, such as BMI in each group. Fourth, although the publication bias was adjusted by the trim-and-fill method, the scarcity of the involved studies with EAT thickness data may affect the credibility of the conclusion.

The EAT measures were associated with the severity and adverse clinical outcomes of COVID-19. The EAT measures might help in prognostic risk stratification of patients with COVID-19.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Not applicable.

None declare. 

Epicardial adipose tissue, inflammatory biomarkers and COVID-19: Is there a possible relationship?

Epicardial adipose tissue and severe Coronavirus Disease 19

Prevalence of obesity among adult inpatients with COVID-19 in France

Effect of obesity and body mass index on coronavirus disease 2019 severity: A systematic review and meta-analysis

Colchicine use in patients with COVID-19: A systematic review and meta-analysis

Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis

Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system

Higher ACE2 expression levels in epicardial cells than subcutaneous stromal cells from patients with cardiovascular disease: Diabetes and obesity as possible enhancer

Obesity as a Potential Predictor of Disease Severity in Young COVID-19 Patients: A Retrospective Study

Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients

Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: A dose-response meta-analysis

The Association of CT-measured Cardiac Indices with Lung Involvement and Clinical Outcome in Patients with COVID-19

Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis

Visceral Adiposity Elevates the Risk of Critical Condition in COVID-19: A Systematic Review and Meta-Analysis

Computed tomography chest in COVID-19: When & why?

Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19

Blood glucose and epicardial adipose tissue at the hospital admission as possible predictors for COVID-19 severity

Metabolic obesity: the paradox between visceral and subcutaneous fat

Obesity in patients with COVID-19: a systematic review and meta-analysis

Local and systemic effects of the multifaceted epicardial adipose tissue depot

Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction

Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart

Epicardial fat inflammation response to COVID-19 therapies

Epicardial Fat Inflammation in Severe COVID-19

Body mass index and Mini Nutritional Assessment-Short Form as predictors of in-geriatric hospital mortality in older adults with COVID-19

Epicardial adipose tissue: fuel for COVID-19-induced cardiac injury?

Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review

Studies using concentric ring bifocal and peripheral add multifocal contact lenses to slow myopia progression in school-aged children: a meta-analysis

Is Growth Hormone Insufficiency the Missing Link Between Obesity, Male Gender, Age, and COVID-19 Severity?

Does epicardial fat contribute to COVID-19 myocardial inflammation?

Cytokine release syndrome in severe COVID-19

Myocardial injury in COVID-19 patients is associated with the thickness of epicardial adipose tissue

Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies

ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity

Cardiac adipose tissue volume and IL-6 level at admission are complementary predictors of severity and short-term mortality in COVID-19 diabetic patients

Visceral adiposity, subcutaneous adiposity, and severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis

Body mass index and outcome in patients with COVID-19: A dose-response meta-analysis

The utility of the Edmonton Obesity Staging System for the prediction of COVID-19 outcomes: a multi-centre study

Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease

Epicardial adipose tissue attenuation in admitted patients with COVID-19

Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis

Coronary artery calcification and epicardial adipose tissue as independent predictors of mortality in COVID-19

The performance of anthropometric tools to determine obesity: a systematic review and meta-analysis

Association of epicardial adipose tissues with obstructive sleep apnea and its severity: A meta-analysis study

Obesity as a predictor for a poor prognosis of COVID-19: A systematic review

Epicardial and pericoronary adipose tissue in severe COVID-19 infection

Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis

Overweight and Obesity Are Associated With Acute Kidney Injury and Acute Respiratory Distress Syndrome, but Not With Increased Mortality in Hospitalized COVID-19 Patients: A Retrospective Cohort Study

Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19

Pre-existing Health Conditions and Epicardial Adipose Tissue Volume: Potential Risk Factors for Myocardial Injury in COVID-19 Patients

Visceral Adiposity and High Intramuscular Fat Deposition Independently Predict Critical Illness in Patients with SARS-CoV-2